EBS News and Press, Emergent Biosolutions Inc. From 10/15/21

GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV) virus-like particle ...

Shuman, Glenn & Stecker announces that it is investigating potential claims against certain officers and directors of Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE: EBS ). Emergent is a biopharmaceutical company that develops vac...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with this event. For further details see: Emergent Biosolutions (EBS) Presents At Global Healthcare Virtual Conference 2021 - Slideshow

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021 GAITHERSBURG, Md. and CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Prov...

EBS is currently being sued for a manufacturing error involving the mixing of ingredients, which may result in the loss of its COVID-19-related transactions. Currently holds material transactions involving COVID-19 and the US Government's Warp Speed Program, as well as AstraZeneca and...

NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of COVID-19 in adult patients at risk of progression to severe disease ...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. About XLV. A list of cheap stocks. For further details see: XLV: Healthcare Dashboard For August

The U.S. is preparing to ship doses of vaccines made by Moderna (MRNA +17.1%) and AstraZeneca (AZN -0.1%) to Mexico, Bloomberg reports. The AstraZeneca doses were produced at an Emergent BioSolutions (EBS +0.7%) plant in Baltimore that has been plagued by manufacturing issues. However, the FD...

EBS recently announced plans to resume manufacturing of the Johnson & Johnson COVID-19 vaccine. Sales of their NARCAN nasal spray improved by almost 46% year-over-year to $106.2 million. We believe investors have overreacted to the manufacturing challenges they experienced in ...

In a regulatory filing yesterday, Emergent BioSolutions (EBS +2.4%) said it had received inquiries and subpoenas from a range of U.S. authorities regarding its ability to conduct COVID-19 vaccine manufacturing. The company’s production plant in Baltimore was subject to an FDA insp...